FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-0287										
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  DEC TIMOTHY C				2. Issuer Name <b>and</b> Ticker or Trading Symbol SUPERNUS PHARMACEUTICALS, INC.  [ SUPN ]								<u>C.</u> (Cr	eck all applic Directo	or (give title		son(s) to Issuer  10% Owner  Other (specify below)		
(Last) (First) (Middle) C/O SUPERNUS PHARMACEUTICALS, INC. 9715 KEY WEST AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 02/22/2022									Senior Vice-President & CFO					
(Street) ROCKVILLE MD 20850 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transa Date (Month/D					ction 2A. Deemed Execution Date,			3. Transaction Code (Instr. 8)  4. Sec Dispo		4. Securit	urities Acquired (A) or sed Of (D) (Instr. 3, 4 ar		5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Dwnership Instr. 4)	
		-	Fable II - D						uired, Dis s, options			or Bene	eficially					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution D if any (Month/Day/		Transaction Code (Instr.				6. Date Exercisa Expiration Date (Month/Day/Yea			7. Title and Amor of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
				Co	ode	v	(A)	(D)	Date Exercisable		piration ite	Title	Amount or Number of Shares					
Employee Stock Option (Right to Buy)	\$32.2	02/22/2022			A		25,000		(1)	02	/22/2032	Common Stock	25,000	\$0	25,000		D	
Restricted Stock Units	(2)	02/22/2022			A		2,000		(3)		(3)	Common Stock	2,000	\$0	2,000		D	

## Explanation of Responses:

- 1. The option vests in four equal annual installments beginning on February 22, 2023.
- $2. \ Each \ restricted \ stock \ unit \ represents \ the \ right \ to \ receive \ one \ share \ of \ Supernus \ common \ stock \ upon \ vesting.$
- $3.\ These\ restricted\ stock\ units\ will\ be\ settled\ in\ common\ stock\ upon\ vesting,\ such\ vesting\ to\ occur\ on\ February\ 22,\ 2023.$

<u>/s/ Timothy C. Dec</u> <u>02/24/2022</u>

\*\* Signature of Reporting Person D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.